Regulatory status
Tesofensine is an investigational compound. It does not have an approved drug label, and no regulatory authority has authorized it for any medical use. Any information below reflects research data only, not evidence of safety or effectiveness.
What tesofensine is
Tesofensine is a small molecule with the chemical formula C17H23Cl2NO and a molecular weight of about 328.3 g/mol (PubChem CID 11370864). It has been studied under research designations including NS 2330 and in combination form as Tesomet. No approved label, brand name, or official mechanism-of-action description exists for this compound.
Trial footprint
Thirteen studies involving tesofensine have been registered on clinicaltrials.gov. The sample of available trials spans multiple conditions and phases, all early-stage investigational work rather than approved-use research:
- A Phase 2 study of Tesomet (a tesofensine-containing combination) with an open-label extension in subjects with Prader-Willi syndrome, which was withdrawn.
- A completed Phase 2 study evaluating three doses of NS 2330 in patients with mild to moderate dementia of the Alzheimer's type.
- A completed Phase 2 safety and efficacy study of tesofensine combined with metoprolol in subjects with type 2 diabetes mellitus.
These trials reflect the range of conditions under investigation and their completion status, not conclusions about safety or benefit.